Skip to content
Sign in

CRSP · NASDAQ

CRISPR Therapeutics AG (CRSP) Stock Price & Fundamentals

$821.93+0.41%+$3.37End-of-day price as of Oct 9, 2026

CRISPR Therapeutics AG (CRSP) closed at $821.93 on Oct 9, 2026, up 0.41% from the previous close of $818.56.

Share price, past year

1Y +6.33%

52-week range $746.29 – $882.81. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$821.93
Sep 30, 2026$805.73
Aug 31, 2026$804.98
Jul 31, 2026$795.57
Jun 30, 2026$789.27
May 29, 2026$805.97
Apr 30, 2026$826.02
Mar 31, 2026$842.02
Feb 27, 2026$852.16
Jan 30, 2026$869.37
Dec 31, 2025$854.17
Nov 28, 2025$776.49
Oct 31, 2025$772.66

Key statistics

Market cap
$79.45B
P/E (TTM)
—
EPS (TTM)
−$4.71
Revenue (TTM)
$13.39M
Net income (TTM)
−$451.14M
Shares outstanding
96.7M
Dividend yield
—
52-week range
$746.29 – $882.81

CRISPR Therapeutics AG's market cap is $79.45B, based on a share price of $821.93 and 96.7M shares outstanding as of Jun 30, 2026.

Financials

CRISPR Therapeutics AG reported revenue of $3.51M for fiscal 2025, down 90.59% from fiscal 2024.

CRISPR Therapeutics AG reported a net loss of $581.60M in fiscal 2025.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
CRISPR Therapeutics AG annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$3.51M−90.6%−$581.60M−16,569.8%−$6.47−$345.93M
FY2024ended Dec 31, 2024$37.31M−90.0%−$366.25M−981.5%−$4.34−$144.68M
FY2023ended Dec 31, 2023$371.21M+30,885.5%−$153.61M−41.4%−$1.94−$269.85M
FY2022ended Dec 31, 2022$1.20M−99.9%−$650.18M−54,271.7%−$8.36−$532.93M
FY2021ended Dec 31, 2021$914.96M+127,154.9%$377.66M41.3%$4.70$457.27M
FY2020ended Dec 31, 2020$719.00K−99.8%−$348.87M−48,520.9%−$5.29−$256.72M
FY2019ended Dec 31, 2019$289.59M+9,169.9%$66.86M23.1%$1.17$49.99M
FY2018ended Dec 31, 2018$3.12M−92.4%−$164.98M−5,281.1%−$3.44−$99.01M
FY2017ended Dec 31, 2017$41.00M+693.9%−$68.36M−166.7%−$1.71−$77.91M
FY2016ended Dec 31, 2016$5.16M—−$23.18M−448.8%−$1.89−$55.88M
CRISPR Therapeutics AG quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$10.18M−$91.15M−$0.94
Q1 FY2026ended Mar 31, 2026$1.46M−$122.93M−$1.28
Q4 FY2025ended Dec 31, 2025$864.00K−$130.61M−$1.32
Q3 FY2025ended Sep 30, 2025$889.00K−$106.44M−$1.17
Q2 FY2025ended Jun 30, 2025$892.00K−$208.55M−$2.40
Q1 FY2025ended Mar 31, 2025$865.00K−$136.00M−$1.58
Q4 FY2024ended Dec 31, 2024$35.69M−$37.31M−$0.41
Q3 FY2024ended Sep 30, 2024$602.00K−$85.94M−$1.01

Company profile

Name
CRISPR Therapeutics AG
Ticker
CRSP
Exchange
NASDAQ
Industry (SEC SIC)
Biological Products, (No Diagnostic Substances)
Headquarters
Baarerstrasse 14, Zug
Incorporated in
V8
Fiscal year ends
December
SEC CIK
0001674416

Recent SEC filings

Frequently asked questions

What is CRISPR Therapeutics AG's stock price?

CRISPR Therapeutics AG (CRSP) closed at $821.93 on Oct 9, 2026, up 0.41% from the previous close of $818.56.

What is CRISPR Therapeutics AG's market cap?

CRISPR Therapeutics AG's market cap is $79.45B, based on a share price of $821.93 and 96.7M shares outstanding as of Jun 30, 2026.

How much revenue does CRISPR Therapeutics AG make?

CRISPR Therapeutics AG reported revenue of $3.51M for fiscal 2025, down 90.59% from fiscal 2024.

Does CRISPR Therapeutics AG pay a dividend?

CRISPR Therapeutics AG's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from CRISPR Therapeutics AG's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures